Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System

Abstract

Chemokines are chemotactic regulators of immune surveillance in physiological and pathological conditions such as inflammation, infection, and cancer. Several chemokines and cognate receptors are constitutively expressed in the central nervous system, not only in glial and endothelial cells but also in neurons, controlling neurogenesis, neurite outgrowth, and axonal guidance during development. In particular, the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, form a functional network that controls plasticity in different brain areas, influencing neurotransmission, neuromodulation, and cell migration, and the dysregulation of this chemokinergic axis is involved in several neurodegenerative, neuroinflammatory, and malignant diseases. CXCR4 primarily mediates the transduction of proliferative signals, while CXCR7 seems to be mainly responsible for scavenging CXCL12. Importantly, the multiple intracellular signalling generated by CXCL12 interaction with its receptors influences hypothalamic modulation of neuroendocrine functions, although a direct modulation of pituitary functioning via autocrine/paracrine mechanisms was also reported. Both CXCL12 and CXCR4 are constitutively overexpressed in pituitary adenomas and their signalling induces cell survival and proliferation, as well as hormonal hypersecretion. In this review we focus on the physiological and pathological functions of immune-related cyto- and chemokines, mainly focusing on the CXCL12/CXCR4-7 axis, and their role in pituitary tumorigenesis. Accordingly, we discuss the potential targeting of CXCR4 as novel pharmacological approach for pituitary adenomas.

CXCR7 regulates breast tumor metastasis and angiogenesis in�vivo and in�vitro

“…Tumor cell survival and proliferation relies on angiogenesis ( 30 ). CXCR7 was identified to be involved in tube formation in vitro , which may induce tumor growth ( 35 ). Although CXCL12-stimulated VEGF expression has been reported in various cells, to the best of our knowledge, CXCL12-regulated VEGF secretion in breast carcinoma cells has not been studied yet.…”

An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs

“…It is proposed that these compounds exhibit selective induction activity against endothelial cells. Phidianidine A is an indole alkaloid isolated from the marine opisthobranch mollusk Phidiana militaris that significantly reduced CXCL12-induced migration in a rat pituitary adenoma cell line at 50 μM [ 208 ]. Sceptrin, a natural bromopyrrole imidazole alkaloid produced by various marine sponges, inhibited cell motility in several cancer cell lines by reducing cell contractility and binding to monomeric actin [ 209 ].…”

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

“…In GEP-NEN, SST 2 expression is inversely correlated with grading and patient outcome, as well as the expression of the chemokine receptor CXCR4 [153,157]. Similarly to SSTs, CXCR4 is often present in highly proliferative and advanced tumors of various origin, and the chemokine-receptor system CXCL12-CXCR4 largely influences neuroendocrine regulation and functions [158,159]. It may represent an additional diagnostic and therapeutic target in NENs [160].…”